Alpha Teknova Inc (NASDAQ: TKNO) introduced the Fill-Tek Dispensing System on September 16, 2026. The proprietary capability allows manufacturers to fill multiple single-use bag sizes and quantities as a single lot, removing per-bag-size minimums associated with fixed manifold designs.

The system addresses complex bioprocessing workflows by allowing customers to specify exact configurations rather than adhering to fill line constraints. This expansion of Teknova’s modular manufacturing platform complements its recently launched AI-driven Build-Tek Custom Configurator.

Operational Capabilities

Fill-Tek operates within Teknova’s ISO-classified cleanrooms under its ISO 13485:2016 certified quality management system. The process uses validated aseptic welds to connect specific combinations of single-use bags to a dispensing vessel.

Key operational features include:

• Filling formats ranging from 250 mL to 200 L single-use bags.
• Tailoring fill volume, number, size, and sequence of QC samples.
• Single batch filtration resulting in one Certificate of Analysis per lot.
• Availability across Research Use Only (RUO), RUO+, and GMP manufacturing grades.

Batch Volume Flexibility

The system supports scalable batch volumes without impacting turnaround times. Custom research-grade orders start at eight liters, while GMP-grade orders begin at 25 liters. Both categories scale up to a maximum batch volume of 2,000 liters.

Strategic Impact

Stephen Gunstream, President and Chief Executive Officer, stated that Fill-Tek removes constraints previously imposed by fixed manifold designs. Bella Neufeld, Vice President of Operations, noted that the system simplifies incoming quality control requirements and minimizes rework by attaching correct connectors for seamless integration into existing bioprocessing systems.

What the Numbers Show

The data highlights a significant divergence in minimum entry barriers between research and commercial-grade manufacturing. While GMP orders require a minimum commitment of 25 liters, research-grade orders allow entry at just 8 liters. This 17-liter gap suggests Teknova is structuring its platform to lower the barrier for early-stage discovery clients while maintaining higher volume thresholds for regulated commercial production, potentially optimizing asset utilization across different workflow stages.

Alpha Teknova, Inc. will report its financial results for the second quarter ended June 30, 2026, on Wednesday, August 5, 2026, following the close of market. The announcement will provide insights into the company's performance for the quarter, covering its production of critical reagents for the life sciences industry.

To discuss the results, Teknova will host a conference call and webcast on August 5, 2026, beginning at 6:00 p.m. Eastern Time. Investors can access the live webcast through the Investor Relations section of the Teknova website or via a direct link provided by the company. Those wishing to participate in the call must register for the webcast to receive a unique PIN number and dial-in details.

A replay of the webcast will be available on the company’s website approximately two hours after the event concludes. This allows stakeholders who cannot attend the live session to access the discussion at their convenience.

Teknova specializes in manufacturing critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Headquartered in Hollister, California, the company supports industry leaders in genomics, molecular diagnostics, and emerging therapeutic modalities with customizable solutions.

For inquiries, Matt Lowell, Chief Financial Officer, serves as the primary investor contact, while Jennifer Henry, Senior Vice President, Marketing, handles media communications.